Celcuity Inc. CELC 深 沪
等待开盘 02-06 09:30:00 美东时间
104.28
-3.310
-3.08%
华盛通- 最 高110.995
- 今 开106.41
- 成交量 89.67万股
- 最 低 103.915
- 昨 收 107.59
- 总市值 48.25亿
- 52周最高 120.315
- 市盈率 静 --
- 换手率 1.94%
- 52周最低 7.575
- 委 比 17.01%
- 总股本 4627.13万
- 历史最高 120.315
- 量 比 1.06
- 振 幅 6.58%
- 历史最低 4.03
- 每 手 1
- 风险率 37.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Xpeng, Serina Therapeutics, Dragonfly Energy Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
02-02 21:07
Celcuity Inc. Director David Dalvey Reports Sale of Common Shares
Celcuity Inc. Director David Dalvey Reports Sale of Common Shares David Dalvey, Director, reported a disposal of common shares of Celcuity Inc. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial in
01-30 05:32
Relay upgraded at Oppenheimer on optimism for zovegalisib
Oppenheimer has upgraded Relay Therapeutics (RLAY) to outperform from perform, noting that its lead asset, zovegalisib, could benefit if an upcoming data readout for Celcuity's (CELC) gedatolisib does...
01-27 01:49
Celcuity granted FDA priority review for breast cancer therapy
Celcuity (CELC) announced on Tuesday that the U.S. Food and Drug Administration (FDA) has granted priority review in connection with its New Drug Application for its lead asset, gedatolisib, targeted ...
01-20 23:54
Celcuity Announces FDA's Acceptance For Filing Its New Drug Application For Gedatolisib In Hormone Receptor Positive PIK3CA Wild-Type Advanced Breast Cancer
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing its
01-20 20:33
Celcuity Announces FDA Acceptance of New Drug Application for Gedatolisib in HR+/HER2-/PIK3CA Wild-Type Advanced Breast Cancer
Celcuity Inc. announced the FDA has accepted for filing its New Drug Application (NDA) for gedatolisib in HR+/HER2- advanced breast cancer and granted Priority Review with a PDUFA goal date of July 17, 2026. Gedatolisib, a multi-target PI3K/AKT/mTOR inhibitor, received Breakthrough Therapy and Fast Track designations. The submission is based on Phase 3 VIKTORIA-1 trial data for the PIK3CA wild-type cohort. The company expects to collaborate with ...
01-20 12:30
2026美股生物科技板块怎么投资？杰富瑞：关注6大首选、7大潜力和5大并购目标
杰富瑞近日发布了关于 2026 年美股生物科技行业的展望报告，聚焦行业首选投资标的、被低估的潜力企业和潜在并购机会。
2025-12-25 15:40
美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
2025-12-15 15:30
Celcuity Announces Updated Results From Randomized, Phase 3 VIKTORIA-1 Trial For Gedatolisib, At 2025 SABCS
For patients whose time to progression on immediate prior therapy was >18 months, median progression-free survival ("PFS") was 12.4 months with gedatolisib + palbociclib + fulvestrant ("gedatolisib triplet") and 10.0
2025-12-12 03:38
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
2025-12-03 09:58
